<p>Most of the new compounds being developed as active pharmaceutical ingredients (API) are practically insoluble in water, which entails low bioavailability when taken orally. The crystal lattice created by API molecules in addition to the chemical structure is the main obstacle to increasing the degree of dissolution. Solid dispersions obtained by recrystallization or fusion of an API with a polymer can increase the solubility of the API to a level exceeding the apparent solubility because of the destruction of the ordered structure of the crystals. However, compounds can often be released into an aqueous medium only if the API is completely amorphized inside a solid dispersion. This is associated with risks related to the stability of the non-crystalline state. The present paper analyzed and studied approaches to the creation and study of long-term amorphous solid dispersions. The causes of recrystallization of the API and problems of the sensitivity of different methods for analyzing the crystallinity of the API were considered.</p>